CONMED Corp (CNMD) Form 8-K — Oct 28, 2026
CONMED Corporation reported Q3 2026 net sales of $335.6 million, down 0.7% year-over-year as reported but up 6.7% on an organic constant currency basis excluding its strategic GI product exits. GAAP diluted EPS was $0.66, up 613.7%, while adjusted diluted EPS of $1.04 was down 3.2% year-over-year but exceeded the company's expectations. The company raised its full-year 2026 adjusted EPS guidance to $4.54-$4.61 from the prior range of $4.48-$4.60 and narrowed sales guidance to $1,360-$1,366 million. Growth was driven by the AirSeal, Buffalo Filter, and BioBrace platforms, with international sales up 13.1% as reported offsetting an 11.0% domestic decline.
Key figures
- Eps
- 0.66
- Revenue
- 335600000
- Guidance
- FY2026 net sales $1,360-$1,366M (prior $1,358-$1,373M); adjusted diluted EPS $4.54-$4.61 (prior $4.48-$4.60); organic constant currency sales growth 5.0-5.5%
- Net Income
- 19796000
- Adjusted eps q3
- 1.04
- Gross margin pct
- 56.4
- Adjusted ebitda q3
- 67878000
- Nine month net sales
- 996090000
- Domestic sales change reported pct
- -11
- International sales change reported pct
- 13.1
- Organic constant currency growth q3 pct
- 6.7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.